An observational study in Non-small Cell Lung Cancer (NSCLC), sponsored by Bristol-Myers Squibb. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-14.
Sponsored by Bristol-Myers Squibb · Observational
The purpose of this study is to assess the treatment-related adverse events and associated healthcare resource use in programmed death ligand 1 (PD-L1) negative individuals diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) who received first-line therapy
6,488 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,632 are open to participants now.
This study's planned enrollment of 300 is above the median of 161 across 949 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
The study population will comprise of programmed death ligand 1 (PD-L1) negative individuals diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) who received first-line therapy in routine clinical practice at the Florida Cancer Specialists and Research Institute
Inclusion Criteria:Inclusion Criteria:
Received one of the following 1L treatments:
Exclusion Criteria:
Participants receiving nivolumab + ipilimumab treatment
Biological: Nivolumab + ipilimumab
Participants receiving nivolumab + ipilimumab + platinum-based chemotherapy
Biological: Nivolumab + ipilimumab + platinum-based chemotherapy
Participants receiving immuno-oncology therapy (excl nivolumab) with chemotherapy treatment
Biological: Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy
Participants receiving other dual-IO with chemotherapy
Biological: Other dual-immuno-oncology therapy with chemotherapy
According to the product label
According to the product label
According to the product label
According to the product label
Incidence of treatment-related adverse events
Time frame: Baseline
Participant baseline clinical characteristics
Time frame: Baseline
Time to onset of treatment-related adverse events
Time frame: Up to 8 years
Number of treatment-related adverse events resolved
Time frame: Up to 8 years
Number of participants receiving treatment for treatment-related adverse events by drug class
Time frame: Up to 8 years
Number of participants that discontinued immune-oncology therapy due to treatment-related adverse events
Time frame: Up to 8 years
Healthcare Resource Utilization (HCRU) associated with treatment-related adverse event
Time frame: Up to 8 years
Plan to share: No
This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung→
Bristol-Myers Squibb